Meeder Asset Management Inc. reduced its position in Pfizer, Inc. (NYSE:PFE) by 29.9% in the second quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 105,352 shares of the biopharmaceutical company’s stock after selling 44,990 shares during the quarter. Meeder Asset Management Inc.’s holdings in Pfizer were worth $3,539,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other large investors have also recently added to or reduced their stakes in the company. Asset Planning Services Ltd. increased its position in Pfizer by 4.9% in the first quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after buying an additional 137 shares during the last quarter. Franklin Parlapiano Turner & Welch LLC purchased a new stake in Pfizer in the first quarter worth $121,000. Patten Group Inc. increased its position in Pfizer by 5.1% in the first quarter. Patten Group Inc. now owns 5,181 shares of the biopharmaceutical company’s stock worth $177,000 after buying an additional 252 shares during the last quarter. Acropolis Investment Management LLC increased its position in Pfizer by 6.7% in the second quarter. Acropolis Investment Management LLC now owns 5,603 shares of the biopharmaceutical company’s stock worth $188,000 after buying an additional 352 shares during the last quarter. Finally, Kimelman & Baird LLC purchased a new stake in Pfizer in the first quarter worth $203,000. 68.99% of the stock is owned by institutional investors and hedge funds.
Shares of Pfizer, Inc. (NYSE:PFE) traded down 0.0398% during midday trading on Tuesday, reaching $36.1256. The company’s stock had a trading volume of 8,644,656 shares. Pfizer, Inc. has a 12 month low of $29.83 and a 12 month high of $36.51. The company’s 50-day moving average price is $34.82 and its 200-day moving average price is $33.69. The company has a market cap of $214.85 billion, a PE ratio of 26.4269 and a beta of 1.00.
Pfizer (NYSE:PFE) last issued its quarterly earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business had revenue of $12.90 billion during the quarter, compared to analyst estimates of $13.08 billion. During the same quarter in the prior year, the business posted $0.64 EPS. Pfizer’s revenue for the quarter was down 1.9% compared to the same quarter last year. On average, equities analysts anticipate that Pfizer, Inc. will post $2.56 EPS for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 1st. Shareholders of record on Friday, November 10th will be paid a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a yield of 3.54%. Pfizer’s payout ratio is presently 94.12%.
In other news, insider Sally Susman sold 38,230 shares of the firm’s stock in a transaction dated Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the completion of the transaction, the insider now owns 145,649 shares in the company, valued at $5,097,715. The sale was disclosed in a document filed with the SEC, which is available at the SEC website. Also, insider Alexander R. Mackenzie sold 15,000 shares of the firm’s stock in a transaction dated Monday, August 7th. The shares were sold at an average price of $33.50, for a total value of $502,500.00. Following the transaction, the insider now owns 151,474 shares of the company’s stock, valued at approximately $5,074,379. The disclosure for this sale can be found here. Insiders sold a total of 464,521 shares of company stock valued at $15,813,961 in the last quarter. 0.06% of the stock is currently owned by company insiders.
A number of analysts have issued reports on PFE shares. Cowen and Company set a $43.00 target price on Pfizer and gave the stock a “buy” rating in a research report on Monday, August 14th. Jefferies Group LLC set a $35.00 price target on Pfizer and gave the company a “neutral” rating in a research report on Thursday, August 24th. Berenberg Bank reiterated a “hold” rating and issued a $36.00 price target (down from $39.00) on shares of Pfizer in a research report on Tuesday, August 15th. BidaskClub cut Pfizer from a “sell” rating to a “strong sell” rating in a research report on Thursday, July 13th. Finally, Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a research report on Friday, July 14th. Two analysts have rated the stock with a sell rating, eight have issued a hold rating and thirteen have assigned a buy rating to the stock. Pfizer currently has an average rating of “Hold” and an average target price of $38.21.
Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).
Want to see what other hedge funds are holding PFE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Pfizer, Inc. (NYSE:PFE).
What are top analysts saying about Pfizer Inc.? - Enter your email address in the form below to receive our free daily email newsletter that contains the latest headlines and analysts' recommendations for for Pfizer Inc. and related companies.